-
JAMA Ophthalmology
Invited Commentary
April 25, 2024
Kevin J.Blinder,Ѷ
online first
JAMA Ophthalmol. 2024; 10.1001/jamaophthalmol.2024.1050
-
JAMA Ophthalmology
Original Investigation
March 1, 2018
Neil M.Bressler,Ѷ; Wesley T.Beaulieu, PhD; Adam R.Glassman, MS; Kevin J.Blinder,Ѷ; Susan B.Bressler,Ѷ; Lee M.Jampol,Ѷ; Michele Melia, ScM; John A.Wells III,Ѷ, MS; for the Diabetic Retinopathy Clinical Research Network
free access
JAMA Ophthalmol. 2018; 136(3):257-269. 10.1001/jamaophthalmol.2017.6565
This secondary analysis of a randomized clinical trial assesses outcomes of diabetic macular edema persisting at least 24 weeks after randomization to treatment with 2.0-mg aflibercept, 1.25-mg bevacizumab, or 0.3-mg ranibizumab.
-
JAMA Ophthalmology
JAMA Ophthalmology Clinical Challenge
May 1, 2017
Nicholas D.Chinskey,Ѷ; Kevin J.Blinder,Ѷ
JAMA Ophthalmol. 2017; 135(5):493-494. 10.1001/jamaophthalmol.2016.4476
A white man in his 50s initially presented in the fall of 2015 with “macular changes” noticed by his referring optometrist. The patient was asymptomatic at the time. He had a history of hypertension and non-Hodgkin lymphoma, which was last treated in 2012 without evidence of recurrence. What would you do next?
-
JAMA Ophthalmology
Original Investigation
August 1, 2014
Gui-shuang Ying, PhD; Benjamin J.Kim,Ѷ; Maureen G.Maguire, PhD; Jiayan Huang, MS; Ebenezer Daniel, PhD; Glenn J.Jaffe,Ѷ; Juan E.Grunwald,Ѷ; Kevin J.Blinder,Ѷ; Christina J.Flaxel,Ѷ; Firas Rahhal,Ѷ; Carl Regillo,Ѷ; Daniel F.Martin,Ѷ; for the CATT Research Group
free access
JAMA Ophthalmol. 2014; 132(8):915-921. 10.1001/jamaophthalmol.2014.1019
Ying and coauthors assess sustained visual acuity loss after 2 years of treatment with ranibizumab or bevacizumab for neovascular age-related macular degeneration.
-
JAMA Ophthalmology
Letters
January 1, 2008
Georges Saab, MD; Arghavan Almony, MD; Kevin J. Blinder, MD; Rebecca Schuessler, RN; Daniel C. Brennan, MD
Arch Ophthalmol. 2008; 126(1):140-141. 10.1001/archophthalmol.2007.23
-
JAMA Ophthalmology
Correspondence
May 1, 2006
Seenu M. Hariprasad, MD; Kevin J. Blinder, MD; Gaurav K. Shah, MD; Rajendra S. Apte, MD, PhD; Brett Rosenblatt, MD; Nancy M. Holekamp, MD; Matthew A. Thomas, MD; William F. Mieler, MD; Jingduan Chi, PhD; Randall A. Prince, PharmD
Arch Ophthalmol. 2006; 124(5):749-749. 10.1001/archopht.124.5.749-b
-
JAMA Ophthalmology
Clinical Sciences
February 1, 2006
Seenu M. Hariprasad, MD; Gaurav K. Shah, MD; William F. Mieler, MD; Leonard Feiner, MD; Kevin J. Blinder, MD; Nancy M. Holekamp, MD; Hua Gao, MD; Randall A. Prince, PharmD
free access
Arch Ophthalmol. 2006; 124(2):178-182. 10.1001/archopht.124.2.178
-
JAMA Ophthalmology
Clinical Sciences
January 1, 2005
Seenu M. Hariprasad, MD; Kevin J. Blinder, MD; Gaurav K. Shah, MD; Rajendra S. Apte, MD, PhD; Brett Rosenblatt, MD; Nancy M. Holekamp, MD; Matthew A. Thomas, MD; William F. Mieler, MD; Jingduan Chi, PhD; Randall A. Prince, PharmD
free access
Arch Ophthalmol. 2005; 123(1):39-44. 10.1001/archopht.123.1.39
-
JAMA Ophthalmology
Photo Essay
August 1, 2004
Blake A. Cooper, MD; Kevin J. Blinder, MD; Gaurav K. Shah, MD; Isaac Boniuk, MD
Arch Ophthalmol. 2004; 122(8):1238-1239. 10.1001/archopht.122.8.1238
-
JAMA Ophthalmology
Article
December 1, 1987
Kevin J. Blinder, MD; Wendell Scott, MD; Mary Pat Lange, MD
Arch Ophthalmol. 1987; 105(12):1632-1633. 10.1001/archopht.1987.01060120030009